Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in Severe Preeclampsia and HELLP Syndrome
NCT06333652Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Apr 2027
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ravulizumab in preeclampsia and HELLP syndrome (HELLP), sponsored by Mayo Clinic. Primary endpoint: Alternative Complement Pathway Biomarkers. Planned start Apr 2027; status: recruiting.
02
Drugs
ravulizumab
03
Conditions
preeclampsiaHELLP syndrome (HELLP)
Beyond the preview
Go deeper on NCT06333652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06333652.